Document Detail

Intracoronary local paclitaxel delivery by X-ray contrast media for in-stent restenosis: a clinical pilot study to assess safety and tolerability.
MedLine Citation:
PMID:  22858919     Owner:  NLM     Status:  In-Data-Review    
AIM: Non-stent-based immediate release formulations of paclitaxel have been shown to reduce in-stent restenosis in animal experiments and clinical trials. In the porcine overstretch model paclitaxel dissolved in the contrast medium iopromide inhibited neointimal proliferation in a dose-dependent manner after intracoronary injection and was well tolerated.
METHODS: As a first step entering clinical development, a phase I trial was performed using four ascending paclitaxel dose/concentration levels: samples of up to 100 mL of the contrast medium (iopromide) containing 10, 50, 100 or 200 µM paclitaxel or iopromide (controls) were randomly administered to patients assigned to bare metal stent implantation for single de novo coronary artery lesions. Safety variables, tolerability and angiographic parameters were assessed.
RESULTS: Adverse events, ECG, systolic and diastolic blood pressure, left ventricular ejection fraction, leukocyte count, other hematological or clinical chemistry data did not reveal any trend which could be related to the study medication. Short-lasting serum paclitaxel concentrations remained significantly below those known from cancer therapy. Angiographic late lumen loss was 0.72±0.50 mm (N.=7) in controls versus 0.45±0.65 mm (N.=17) in all paclitaxel-treated patients; binary restenosis rate was 5/7(63%) versus 6/17 (35%) and target lesion revascularization rate was 4/8 (50%) versus 4/24 (17%).
CONCLUSION: Intracoronary infusion of paclitaxel dissolved in an X-ray contrast medium was well tolerated. The results show restenosis inhibition, but the number of patients examined was too small to demonstrate a statistically significant inhibition.
W Rutsch; B Scheller; A C Borges; M Bräutigam; Y Clever; B Cremers; U Dietz; W Richter; U Speck
Related Documents :
24893299 - Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in co...
7697849 - Randomized study of implantable defibrillator as first-choice therapy versus convention...
22823449 - Safety and long-term outcome of modified intracardiac echocardiography-assisted "no-bal...
7605519 - Effect of age on prehospital cardiac resuscitation outcome.
23021009 - Low rates of hepatotoxicity among asian patients with paracetamol overdose: a review of...
11163559 - Pretreatment of human myocardium with adenosine.
25170249 - Evaluation of the relationship between corneal biomechanic and hba1c levels in type 2 d...
16109519 - Prevention and management of pleural effusion following hepatectomy in primary liver ca...
2404389 - A randomized pilot trial of brief versus prolonged heparin after successful reperfusion...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  60     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  415-23     Citation Subset:  IM    
HELIOS Klinikum Emil-von-Behring,, Berlin, Germany -
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Severe intermittent claudication: pge1 treatment. A 40-week registry, efficacy and costs.
Next Document:  Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation...